Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
Explore this paper's citation graph
Summary
The R-ZES is safe and effective in patients with diabetes, and long-term clinical data of patients with noninsulin-treated diabetes are equivalent to patients without diabetes.
- Type
- article
- Published
- 2013-04-01
- Cited by
- 93
- References
- 48
- Access
- Open access
- OpenAlex
- https://openalex.org/W34784395
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:23525850
Keywords
Medicine, Percutaneous coronary intervention, Diabetes mellitus, Zotarolimus, Internal medicine
References
- Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial.
- Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
- One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients.
- Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry.
- Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
- Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial.
- Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial.
- Strategies for multivessel revascularization in patients with diabetes.
- Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
- Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study).
- PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses.
- Rationale and design of the clinical evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical trial).
- Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era.
- Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents.
- Comparative Effects of Paclitaxel and Rapamycin on Smooth Muscle Migration and Survival: Role of Akt-Dependent Signaling
- Strategies for multivessel revascularization in patients with diabetes.
- Guidelines on myocardial revascularization.
- Meta-analysis of five randomized clinical trials comparing sirolimus- versus paclitaxel-eluting stents in patients with diabetes mellitus.
- Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry.
- Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients.
Cited by
- Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
- Non-Inferiority of Resolute Integrity Drug-Eluting Stent to Benchmark Xience Drug-Eluting Stent.
- Contemporary Outcomes of Coronary Artery Bypass Grafting Among Patients With Insulin-Treated and Non-Insulin-Treated Diabetes.
- Comparison of outcomes after everolimus-eluting stent implantation in diabetic versus non-diabetic patients in the Tokyo-MD PCI study.
- Drug‐eluting stents and diabetes
- Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program.
- One‐year clinical outcomes after sirolimus‐eluting coronary stent implantation in diabetics enrolled in the worldwide e‐SELECT registry
- Performance of the resolute zotarolimus‐eluting stent in small vessels
- Influence of low shear and cyclic strain on hyperglycemic rat aortic smooth muscle cells: An In Vitro dynamic disease model
- Polymer‐free stents in diabetic patients—not so sweet after all!
- Biolimus-Eluting StenT For de-novo coRonary artery dIsease in patiENts with Diabetes mellituS: the BESTFRIENDS multicentre registry
- Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
- Prospective, multi-center evaluation of a silicon carbide coated cobalt chromium bare metal stent for percutaneous coronary interventions: two-year results of the ENERGY Registry.
- Everolimus-eluting versus sirolimus-eluting coronary stents in patients with and without diabetes mellitus.
- Revascularization in Patients with Diabetes: PCI or CABG or None at All
- A clinical update on the use of Resolute stents with dual anti-platelet therapy interruption
- Comparison of Zotarolimus-Eluting stent versus Sirolimus-Eluting stent for de novo coronary artery disease in patients with diabetes mellitus from the ESSENCE-DIABETES II trial.
- Percutaneous Coronary Intervention in Patients With Diabetes
- Coronary artery disease and diabetes mellitus
- Coronary Artery Revascularization in Patients with Diabetes
Related papers
- AS-144: Impact of Age on the Percutaneous Coronary Intervention Outcomes in the Drug-Eluting Stent Era
- Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial.
- One-year outcomes of percutaneous coronary intervention with the 38-mm Resolute zotarolimus-eluting stent.
- Impact of coronary lesion complexity in percutaneous coronary intervention: one-year outcomes from the large, multicentre e-Ultimaster registry.
- Angioscopic differences in neointimal coverage between zotarolimus- and everolimus-eluting stents
- Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial.
- Everolimus- versus zotarolimus-eluting stent following percutaneous coronary chronic total occlusion intervention.
- The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutan
- One year clinical outcomes in patients with chronic kidney disease treated by percutaneous coronary intervention with drug-eluting stent.
- One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry.